Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study

This study has been completed.
Sponsor:
Collaborator:
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Information provided by:
Indiana University
ClinicalTrials.gov Identifier:
NCT00871234
First received: March 27, 2009
Last updated: January 5, 2011
Last verified: December 2010
Results First Received: December 7, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label
Conditions: Endothelial Function
Lipids
Insulin Resistance
Inflammation
HIV Infections
Intervention: Drug: Etravirine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment occurred between April 2009 and March 2010. Participants were recruited via advertisements and word-of-mouth.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
After participant enrollment, a screening visit was performed to determine eligibility. Participants may have been excluded from entering the study if they were found to be ineligible.

Reporting Groups
  Description
Etravirine Healthy volunteers receiving etravirine 200mg orally twice daily

Participant Flow:   Overall Study
    Etravirine  
STARTED     28  
COMPLETED     23  
NOT COMPLETED     5  
Adverse Event                 2  
Lost to Follow-up                 3  



  Baseline Characteristics


  Outcome Measures

1.  Primary:   Flow-mediated Dilation (FMD) of the Brachial Artery   [ Time Frame: Entry and four weeks ]

2.  Secondary:   Lipid Fractions   [ Time Frame: Four weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   Yes

3.  Secondary:   Insulin Sensitivity [(Homeostasis Model Assessment-Insulin Resistance (HOMA-IR)]   [ Time Frame: Four weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   Yes

4.  Secondary:   Blood Pressure   [ Time Frame: Four weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   Yes

5.  Secondary:   Inflammatory Biomarkers   [ Time Frame: Four weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   Yes

6.  Secondary:   Endothelial Activation Biomarkers   [ Time Frame: Four weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   Yes


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information